Edap Tms (EDAP) Stock Price
Edap Tms Price
Over the last 19 years Edap Tms grew revenue by 6.1% annually, reaching 70.75 M EUR. Earnings per share have declined at 15.1% per year over the last 13 years. For Edap Tms, the net margin of -41.5% is down versus 1.6% a few years ago. The consensus 12-month price target for Edap Tms is 3.54 EUR, about 37.7% below where the stock trades today. Of 9 analysts, 6 rate the stock a buy — an overall Buy consensus.
Edap Tms stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Edap Tms over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Edap Tms stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Edap Tms's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Edap Tms Price |
|---|---|
| 7/20/2026 | 5.68 EUR |
| 7/1/2026 | 5.18 EUR |
| 6/17/2026 | 4.81 EUR |
| 6/15/2026 | 4.75 EUR |
| 6/11/2026 | 4.72 EUR |
| 5/14/2026 | 3.54 EUR |
Edap Tms Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Edap Tms Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.00 | 40.00 | 40.00 | 44.00 | 51.00 | 47.00 | 50.00 | 62.00 | 68.00 | 73.00 | 70.00 | 51.00 | 56.00 | 64.00 | 94.00 | 113.00 |
| 20.00 | 11.11 | – | 10.00 | 15.91 | -7.84 | 6.38 | 24.00 | 9.68 | 7.35 | -4.11 | -27.14 | 9.80 | 14.29 | 46.88 | 20.21 |
| 41.67 | 45.00 | 40.00 | 43.18 | 45.10 | 42.55 | 40.00 | 43.55 | 39.71 | 41.10 | 42.86 | 42.86 | 42.86 | 42.86 | 42.86 | 42.86 |
| 15.00 | 18.00 | 16.00 | 19.00 | 23.00 | 20.00 | 20.00 | 27.00 | 27.00 | 30.00 | 30.00 | 21.86 | 24.00 | 27.43 | 40.29 | 48.43 |
| – | – | -2.00 | -1.00 | 2.00 | – | -1.00 | -4.00 | -22.00 | -23.00 | -28.00 | -10.00 | -11.00 | -13.00 | -19.00 | -23.00 |
| – | – | -5.00 | -2.27 | 3.92 | – | -2.00 | -6.45 | -32.35 | -31.51 | -40.00 | -19.61 | -19.64 | -20.31 | -20.21 | -20.35 |
| -1.00 | 4.00 | – | – | 1.00 | -1.00 | – | -3.00 | -24.00 | -21.00 | -29.00 | -25.00 | -19.00 | -15.00 | -2.00 | 3.00 |
| – | -500.00 | – | – | – | -200.00 | – | – | 700.00 | -12.50 | 38.10 | -13.79 | -24.00 | -21.05 | -86.67 | -250.00 |
| 28.85 | 28.73 | 29.00 | 29.35 | 29.05 | 30.22 | 34.56 | 36.92 | 37.07 | 37.23 | 37.45 | 37.45 | 37.45 | 37.45 | 37.45 | 37.45 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Edap Tms generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Edap Tms retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Edap Tms's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Edap Tms has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Edap Tms's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Edap Tms stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Edap Tms Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Edap Tms business model & stock analysis
Edap Tms SWOT Analysis
Strengths
Edap Tms SA possesses several strengths that contribute to its competitive advantage:
- Advanced medical technology and expertise
- Strong intellectual property portfolio
- Established global presence and distribution network
- Proven track record of successful product development
- Strong financial performance and stability
Weaknesses
Despite its strengths, Edap Tms SA faces certain weaknesses that may hinder its growth:
- Reliance on a limited product portfolio
- Potential vulnerability to market fluctuations
- Dependency on key personnel and experts
- Need for continuous investment in research and development
- Limited market share compared to some competitors
Opportunities
There are several opportunities for Edap Tms SA to exploit and expand its business:
- Growing demand for minimally invasive medical procedures
- Emerging markets with untapped potential
- Increased healthcare spending worldwide
- Potential partnerships and collaborations
- Technological advancements in medical devices
Threats
Despite the opportunities, Edap Tms SA must also face certain threats that could impact its operations:
- Intense competition from established market players
- Regulatory and compliance challenges
- Economic downturns affecting healthcare budgets
- Uncertainty surrounding healthcare policies
- Rapid technological advancements leading to product obsolescence
Edap Tms Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Edap Tms Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Edap Tms historical P/E ratio, EBIT multiple, and P/S ratio
Edap Tms annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Edap Tms shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Edap Tms forecasts and price targets in August 2026
Analyst Price Targets 2026Edap Tms Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 6/2/2026 | Maintained | Buy | – | |
| 4/9/2026 | Maintained | Buy | – | |
| 4/4/2025 | Downgrade | BuyHold | 47 | |
| 3/28/2025 | Maintained | Overweight | 51 | |
| 3/28/2025 | Maintained | Buy | – | |
| 8/29/2024 | Maintained | Buy | – | |
| 7/22/2024 | Maintained | Buy | – | |
| 5/17/2024 | Maintained | Buy | – | |
| 4/1/2024 | Maintained | Buy | – | |
| 11/10/2023 | Maintained | Overweight | 51 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Edap Tms Earnings Calls
Edap Tms Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 5/7/2026 | -0.19EUR | - | 14.44 MEUR | - | 2026 Q1 |
| 3/25/2026 | -0.13EUR | - | 18.73 MEUR | - | 2025 Q4 |
| 11/7/2024 | -0.15EUR | - | 15.54 MEUR | - | 2024 Q3 |
| 5/15/2024 | -0.09EUR | - | 14.63 MEUR | - | 2024 Q1 |
| 3/28/2024 | -0.05EUR | - | 16.83 MEUR | - | 2023 Q4 |
| 11/14/2023 | -0.05EUR | - | 15.59 MEUR | - | 2023 Q3 |
| 8/22/2023 | -0.02EUR | - | 15.72 MEUR | - | 2023 Q2 |
| 5/15/2023 | -0.01EUR | - | 14.58 MEUR | - | 2023 Q1 |
| 3/28/2023 | -0.01EUR | - | 15.45 MEUR | - | 2022 Q4 |
| 11/16/2022 | -0.06EUR | - | 12.23 MEUR | - | 2022 Q3 |
Edap Tms shareholder structure
| % | Name |
|---|---|
19.54869% | |
8.99326% | |
3.39663% | |
1.48075% | |
0.60521% | |
0.46717% |
Edap Tms Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
25.00% | SEC ↗ | |
9.15% | SEC ↗ | |
9.15% | SEC ↗ | |
9.00% | SEC ↗ | |
7.00% | SEC ↗ | |
6.40% | SEC ↗ | |
6.30% | SEC ↗ | |
5.90% | SEC ↗ | |
5.57% | SEC ↗ | |
4.83% | SEC ↗ |
Edap Tms Executives and Management Board
13 members · avg. age 59 · 15 % women
Management
Mr. Ryan Rhodes (63)
Chief Executive Officer, Director, Chief Executive Officer of EDAP Technomed Inc · since 2021
Mr. Kenneth Mobeck (54)
Chief Financial Officer
Mr. Jean-Francois Bachelard (61)
President and Chief Executive Officer of Edap Technomed Co Ltd (Japan)
Mr. Frederic Pech (56)
President of EDAP TMS France SAS
Mr. Francois Dietsch (49)
Chief Accounting Officer
Ms. Blandine Confort
Investor Relations Officer, Director - Legal Affairs
Board of Directors
Dr. Lance Willsey (63)
Interim Independent Chairman of the Board · since 2023
Mr. Glen French (62)
Independent Director
Mr. Josh Levine (64)
Independent Director
Ms. Fran Schulz (61)
Independent Director
Frequently asked questions about Edap Tms
The business model of Edap Tms SA revolves around providing innovative medical devices and solutions for the treatment of urology and other diseases. With a focus on High-Intensity Focused Ultrasound (HIFU) technology, Edap Tms SA aims to enhance patient care and offer non-invasive, personalized treatment options. By developing cutting-edge medical devices such as Ablatherm® and Focal One®, the company enables healthcare professionals to perform precise and targeted therapeutic procedures. Edap Tms SA's business model emphasizes continuous research and development to stay at the forefront of medical technology advancements, ultimately improving patient outcomes in urology and beyond.
Edap Tms SA is primarily active in the medical technology industry.
The main competitors of Edap Tms SA in the market include companies such as Intuitive Surgical Inc., Siemens AG, and SonaCare Medical LLC.
Edap Tms SA is a leading global provider of innovative medical devices specializing in therapeutic ultrasound. Established in 1979, the company has a rich history of technological advancements in the field. Edap Tms SA's technology utilizes focused ultrasound waves to precisely treat a range of medical conditions, including urological and musculoskeletal disorders. With decades of experience, the company has earned a strong reputation for its cutting-edge solutions and commitment to improving patient outcomes. Edap Tms SA is dedicated to advancing non-invasive therapies and remains at the forefront of medical technology, consistently delivering groundbreaking solutions to healthcare professionals worldwide.
Some significant milestones that the company Edap Tms SA has achieved include: 1. In 2001, the company received FDA approval for their Ablatherm® High Intensity Focused Ultrasound (HIFU) system for the treatment of prostate cancer. 2. In 2015, Edap Tms SA announced the completion of a landmark study demonstrating the long-term efficacy and safety of their Ablatherm HIFU system. 3. In 2017, the company received FDA clearance for its Focal One® HIFU system, offering a non-invasive treatment option for localized prostate cancer. 4. Edap Tms SA has expanded its market presence globally, with installations of their HIFU systems in over 35 countries worldwide. 5. The company continues to innovate and develop new applications for their HIFU technology, driving advancements in minimally invasive treatments for various medical conditions.
Edap Tms SA is primarily present in several countries and regions. These include the United States, Europe, Asia, and Latin America.
Edap Tms SA represents values of innovation, commitment, and excellence in the field of medical technology. As a global leader in therapeutic ultrasound, Edap Tms SA is dedicated to providing cutting-edge solutions for the treatment of urological conditions. With a strong corporate philosophy centered around patient care and continuous improvement, the company strives to deliver safe and effective medical devices that positively impact patients' lives. By combining advanced technology, scientific expertise, and a customer-centric approach, Edap Tms SA remains at the forefront of advancing minimally invasive therapies in the healthcare industry.
Analysts currently set an average price target of 6.05 EUR for the Edap Tms stock (median: 3.54 EUR), implying +6.5 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Edap Tms stock: 6 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Edap Tms to generate revenue of 51.59 M EUR and earnings per share of -0.68 EUR.
The Edap Tms share (EDAP) is listed on 3 stock exchanges, including: NASDAQ (EDAP), Frankfurt (EDA.F), München (EDA.MU).
The company Edap Tms SA is a global provider of medical systems specializing in advanced medical technologies and products. They focus on two main areas: HIFU and Urology. HIFU stands for High-Intensity Focused Ultrasound and refers to the non-invasive treatment of tumors and other tissue abnormalities. The technology uses focused ultrasound energy to destroy tumor cells without damaging surrounding healthy tissue. Edap Tms SA offers a variety of HIFU systems, including Ablatherm® systems, which can be used for the treatment of prostate cancer as well as other medical conditions such as bladder, kidney, and liver tumors. The company also offers a wide range of urological solutions, including lithotripsy or stone removal technologies. These systems are frequently used by urologists for the removal of kidney stones and other urinary tract disorders. The lithotripsy technology works by using high-frequency sound waves to pulverize the stones into small pieces that can then be naturally passed out of the body. The company also offers other urological treatment solutions, including the "Sonolith i-move" technology, which allows doctors to be more flexible and adjust the device's position to meet the needs of the patient and the physician. These solutions are readily available and offer high-performance portable options for doctors and other users, as well as a wide range of accessories and spare parts. The company primarily distributes its products through a well-established global network of suppliers and distributors that support the demand for this technology worldwide. It also invests heavily in research and development to maintain and expand its market-leading position in non-invasive surgical treatment technologies for tumors and stones. Another important element for Edap Tms SA is its strong partnerships with leading medical institutions and research facilities to provide the latest opportunities and innovations in medical technology. In summary, Edap Tms SA has a highly successful business model that focuses on providing HIFU and urological solutions for the global market. It has a strong presence in this diverse and emerging field, is well-diversified, and supported by strategic partnerships and distributors. The company offers a wide range of products with innovative technologies and is well-positioned to deliver advanced solutions to medical professionals and patients worldwide in the face of the challenges and demands of the current medical landscape.
The expected revenue of Edap Tms is 51.59 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Edap Tms is -25.33 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Edap Tms is currently -8.40. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Edap Tms stock.
The price-to-sales ratio (P/S) of Edap Tms is currently 4.12. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Edap Tms stock.
The Eulerpool Quality Score for Edap Tms is 2/10.
The ISIN of Edap Tms is US2683111072. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Edap Tms is 908548. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Edap Tms is EDAP. The ticker symbol is used to trade Edap Tms shares on the stock exchange.
Edap Tms paid dividends every year for the past 0 years.
Edap Tms is assigned to the 'Health' sector.
The dividends of Edap Tms are distributed in EUR.
Edap Tms stock
Edap Tms Peer Group
Edap Tms Ticker
Edap Tms FIGI
All fundamentals and in-depth analysis of Edap Tms
Our stock analysis for Edap Tms stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Edap Tms. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.